drugset / Trial / NCT00207103
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2004-09
- Primary completion
- 2007-10
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brivanib | Small molecule | 180 mg | Oral |
| Subject | Brivanib | Small molecule | 320 mg | Oral |
| Subject | Brivanib | Small molecule | 600 mg | Oral |
| Subject | Brivanib | Small molecule | 800 mg | Oral |
| Subject | Brivanib | Small molecule | 1000 mg | Oral |